Spruce Biosciences Targets Q4 BLA Submission for MPS IIIB Therapy TA-ERT
Event summary
- Spruce Biosciences anticipates submitting a Biologics License Application (BLA) for TA-ERT in Q4 2026, targeting accelerated approval for MPS IIIB treatment.
- The company secured a $5.5 million strategic investment from Cure Sanfilippo Foundation and National MPS Society to support its Expanded Access Program.
- Spruce appointed Adrian Quartel as Chief Medical Officer and Jessica Cohen Pfeffer as Vice President of Clinical Development to strengthen leadership ahead of potential FDA approval.
- Cash reserves stood at $96.3 million as of June 30, 2026, sufficient to fund operations into the second half of 2027.
The big picture
Spruce Biosciences is advancing its lead candidate, TA-ERT, through critical regulatory milestones with the aim of becoming the first FDA-approved therapy for MPS IIIB. The strategic investment from patient advocacy groups underscores the unmet medical need and potential market impact of TA-ERT. The company's strengthened leadership team positions it to navigate the complexities of rare disease drug development and commercialization.
What we're watching
- Regulatory Milestones
- The success of the BLA submission and subsequent FDA review will determine the timeline for TA-ERT's potential commercial launch.
- Clinical Development
- The initiation of the TrAnsform confirmatory study in Q4 2026 is critical for meeting FDA requirements for accelerated approval.
- Financial Sustainability
- Monitoring cash burn and operational efficiency will be key as Spruce progresses toward commercialization.